Patents by Inventor Gerald McMahon

Gerald McMahon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrole substituted 2-indolinone protein kinase inhibitors
    Publication number: 20030105151
    Abstract: The present invention relates to novel pyrrole substituted 2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: February 25, 2002
    Publication date: June 5, 2003
    Applicant: SUGEN, INC.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • 2-indolinone derivatives as modulators of protein kinase activity
    Patent number: 6569868
    Abstract: The present invention relates to novel imidazoly 2-indolinones and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: May 27, 2003
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, G. David Harris
  • 3-(Piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
    Publication number: 20030069421
    Abstract: The present invention relates to novel 3-(piperazinyl-benylidenyl)-2-indolinone compounds and derivatives and physiologically acceptable salts thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Application
    Filed: July 24, 2002
    Publication date: April 10, 2003
    Applicant: SUGEN, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Laura Kay Shawver, Klaus Peter Hlrth
  • 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
    Patent number: 6506763
    Abstract: The present invention relates to novel 3-(substituted)-2-indolinones compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related disorders such as cancer.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: January 14, 2003
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
    Publication number: 20020183319
    Abstract: This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors.
    Type: Application
    Filed: December 21, 2000
    Publication date: December 5, 2002
    Inventors: Congxin Liang, Li Sun, Chung Chen Wei, Peng Cho Tang, Gerald McMahon, Klaus Peter Hirth, Jingrong Cui
  • 3-(cycloalkanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
    Publication number: 20020183370
    Abstract: The present invention relates to novel 3-(cycloalkano-heteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Application
    Filed: December 31, 2001
    Publication date: December 5, 2002
    Applicant: SUGEN, INC.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • 3-heteroarylidene-2-indolinone protein kinase inhibitors
    Patent number: 6486185
    Abstract: The present invention relates to novel 3-heteroarylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: November 26, 2002
    Assignee: Sugen, Inc.
    Inventors: Gerald McMahon, Peng Cho Tang, Li Sun
  • Bicyclic protein kinase inhibitors
    Publication number: 20020156083
    Abstract: The present invention relates to novel 3-hetero-arylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: March 29, 2001
    Publication date: October 24, 2002
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Bis-indolyquinone compounds
    Publication number: 20020156116
    Abstract: The present invention relates to a class of indolylquinone compounds that inhibit GRB-2 adaptor protein function, pharmaceutical compositions comprising these compounds, and methods for ameliorating the symptoms of cell proliferative disorders associated with GRB-2 adaptor protein function using these compounds. The present invention further relates to methods for treating insulin-related disorders, such as diabetes, insulin resistance, insulin deficiency and insulin allergy, and for ameliorating the symptoms of insulin-related disorders, using certain indolylquinone compounds and pharmaceutical compositions thereof. The present invention also relates to novel synthetic methods for the preparation of mono- and bis-indolylquinone compounds.
    Type: Application
    Filed: May 4, 2000
    Publication date: October 24, 2002
    Inventors: Peng Cho Tang, Gerald McMahon, G. Davis Harris, Ken Lipson
  • 3-(4?-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
    Patent number: 6469032
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: October 22, 2002
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Indolinone combinatorial libraries and related products and methods for the treatment of disease
    Publication number: 20020102608
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: July 3, 2001
    Publication date: August 1, 2002
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
  • Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
    Publication number: 20020065283
    Abstract: The present invention relates to novel heteroaryl-carboxamides which modulate the activity of protein tyrosine kinases and therefore are expected to be useful in the treatment of abnormal protein tyrosine kinase activity driven disorders including cancer.
    Type: Application
    Filed: September 7, 2001
    Publication date: May 30, 2002
    Inventors: Gerald McMahon, Peng Cho Tang, Laura Kay Shawver, Klaus Peter Hirth
  • Pyrrole substituted 2-indolinone protein kinase inhibitors
    Patent number: 6395734
    Abstract: The present invention relates to novel pyrrole substituted 2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: May 28, 2002
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Bioavailability 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
    Publication number: 20020058661
    Abstract: The present invention relates to novel 3-hetero-arylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which have improved hydrosolubility and which are expected to modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Application
    Filed: September 7, 2001
    Publication date: May 16, 2002
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
    Publication number: 20020055511
    Abstract: The present invention relates to tricyclic quinoxaline compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Application
    Filed: November 9, 2001
    Publication date: May 9, 2002
    Applicant: SUGEN, INC.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
    Patent number: 6376529
    Abstract: The present invention relates to a class of indolylquinone compounds that inhibit GRB-2 adaptor protein function, pharmaceutical compositions comprising these compounds, and methods for ameliorating the symptoms of cell proliferative disorders associated with GRB-2 adaptor protein function using these compounds. The present invention further relates to methods for treating insulin-related disorders, such as diabetes, insulin resistance, insulin deficiency and insulin allergy, and for ameliorating the symptoms of insulin-related disorders, using certain indolylquinone compounds and pharmaceutical compositions thereof. The present invention also relates to novel synthetic methods for the preparation of mono- and bis-indolylquinone compounds.
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: April 23, 2002
    Inventors: Peng Cho Tang, Gerald McMahon, G. Davis Harris, Jr., Ken Lipson
  • 2-indolinone derivatives as modulators of protein kinase activity
    Publication number: 20020028840
    Abstract: The present invention relates to novel imidazoly 2-indolinones and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: July 6, 2001
    Publication date: March 7, 2002
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, G. Davis Harris
  • Novel 3-(substituted) -2- indolinones compounds and use thereof as inhibitors of protein kinase activity
    Publication number: 20020026053
    Abstract: The present invention relates to novel 3-(substituted)-2-indolinones compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related disorders such as cancer.
    Type: Application
    Filed: July 30, 2001
    Publication date: February 28, 2002
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • 3-(cycloalkanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
    Patent number: 6350754
    Abstract: The present invention relates to novel 3-(cycloalkano-heteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: January 12, 2000
    Date of Patent: February 26, 2002
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Indolinone combinatorial libraries and related products and methods for the treatment of disease
    Publication number: 20020022626
    Abstract: The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1′ position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety.
    Type: Application
    Filed: July 13, 2000
    Publication date: February 21, 2002
    Inventors: Peng Cho Tang, LI Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver